FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy
Source: Targeted Oncology, October 2023
A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.
- An investigational new drug (IND) has been accepted by the FDA for KSQ-001EX .
- KSQ-001Ex is an engineered tumor infiltrating lymphocyte (TIL).
- A phase 1/2 study will begin with this approval.
The FDA has approved an IND application for a phase 1/2 study of KSQ-001EX, an engineered TIL program, according to a press release from KSQ Therapeutics.